Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.

AbuHammad S, Cullinane C, Martin C, Bacolas Z, Ward T, Chen H, Slater A, Ardley K, Kirby L, Chan KT, Brajanovski N, Smith LK, Rao AD, Lelliott EJ, Kleinschmidt M, Vergara IA, Papenfuss AT, Lau P, Ghosh P, Haupt S, Haupt Y, Sanij E, Poortinga G, Pearson RB, Falk H, Curtis DJ, Stupple P, Devlin M, Street I, Davies MA, McArthur GA, Sheppard KE.

Proc Natl Acad Sci U S A. 2019 Sep 3;116(36):17990-18000. doi: 10.1073/pnas.1901323116. Epub 2019 Aug 22.

2.

A functional genetic screen defines the AKT-induced senescence signaling network.

Chan KT, Blake S, Zhu H, Kang J, Trigos AS, Madhamshettiwar PB, Diesch J, Paavolainen L, Horvath P, Hannan RD, George AJ, Sanij E, Hannan KM, Simpson KJ, Pearson RB.

Cell Death Differ. 2019 Jul 8. doi: 10.1038/s41418-019-0384-8. [Epub ahead of print]

PMID:
31285545
3.

First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.

Khot A, Brajanovski N, Cameron DP, Hein N, Maclachlan KH, Sanij E, Lim J, Soong J, Link E, Blombery P, Thompson ER, Fellowes A, Sheppard KE, McArthur GA, Pearson RB, Hannan RD, Poortinga G, Harrison SJ.

Cancer Discov. 2019 Aug;9(8):1036-1049. doi: 10.1158/2159-8290.CD-18-1455. Epub 2019 May 15.

PMID:
31092402
4.

Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation.

Diesch J, Bywater MJ, Sanij E, Cameron DP, Schierding W, Brajanovski N, Son J, Sornkom J, Hein N, Evers M, Pearson RB, McArthur GA, Ganley ARD, O'Sullivan JM, Hannan RD, Poortinga G.

Commun Biol. 2019 Jan 28;2:39. doi: 10.1038/s42003-019-0284-y. eCollection 2019.

5.

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.

Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N; Australian Ovarian Cancer Study (AOCS), deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL.

Nat Commun. 2018 Sep 28;9(1):3970. doi: 10.1038/s41467-018-05564-z.

6.

Ribosomal DNA copy loss and repeat instability in ATRX-mutated cancers.

Udugama M, Sanij E, Voon HPJ, Son J, Hii L, Henson JD, Chan FL, Chang FTM, Liu Y, Pearson RB, Kalitsis P, Mann JR, Collas P, Hannan RD, Wong LH.

Proc Natl Acad Sci U S A. 2018 May 1;115(18):4737-4742. doi: 10.1073/pnas.1720391115. Epub 2018 Apr 18.

7.

Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.

Martin CA, Cullinane C, Kirby L, Abuhammad S, Lelliott EJ, Waldeck K, Young RJ, Brajanovski N, Cameron DP, Walker R, Sanij E, Poortinga G, Hannan RD, Pearson RB, Hicks RJ, McArthur GA, Sheppard KE.

Int J Cancer. 2018 May 15;142(10):2139-2152. doi: 10.1002/ijc.31220. Epub 2018 Jan 3.

8.

Topoisomerase 1 Inhibition Promotes Cyclic GMP-AMP Synthase-Dependent Antiviral Responses.

Pépin G, Nejad C, Ferrand J, Thomas BJ, Stunden HJ, Sanij E, Foo CH, Stewart CR, Cain JE, Bardin PG, Williams BRG, Gantier MP.

MBio. 2017 Oct 3;8(5). pii: e01611-17. doi: 10.1128/mBio.01611-17.

9.

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.

Hein N, Cameron DP, Hannan KM, Nguyen NN, Fong CY, Sornkom J, Wall M, Pavy M, Cullinane C, Diesch J, Devlin JR, George AJ, Sanij E, Quin J, Poortinga G, Verbrugge I, Baker A, Drygin D, Harrison SJ, Rozario JD, Powell JA, Pitson SM, Zuber J, Johnstone RW, Dawson MA, Guthridge MA, Wei A, McArthur GA, Pearson RB, Hannan RD.

Blood. 2017 May 25;129(21):2882-2895. doi: 10.1182/blood-2016-05-718171. Epub 2017 Mar 10.

10.

The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.

Yan S, Frank D, Son J, Hannan KM, Hannan RD, Chan KT, Pearson RB, Sanij E.

Int J Mol Sci. 2017 Jan 20;18(1). pii: E210. doi: 10.3390/ijms18010210. Review.

11.

Cell cycle and growth stimuli regulate different steps of RNA polymerase I transcription.

Hung SS, Lesmana A, Peck A, Lee R, Tchoubrieva E, Hannan KM, Lin J, Sheppard KE, Jastrzebski K, Quinn LM, Rothblum LI, Pearson RB, Hannan RD, Sanij E.

Gene. 2017 May 15;612:36-48. doi: 10.1016/j.gene.2016.12.015. Epub 2016 Dec 15.

PMID:
27989772
12.

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling.

Quin J, Chan KT, Devlin JR, Cameron DP, Diesch J, Cullinane C, Ahern J, Khot A, Hein N, George AJ, Hannan KM, Poortinga G, Sheppard KE, Khanna KK, Johnstone RW, Drygin D, McArthur GA, Pearson RB, Sanij E, Hannan RD.

Oncotarget. 2016 Aug 2;7(31):49800-49818. doi: 10.18632/oncotarget.10452.

13.

Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription.

Kang J, Kusnadi EP, Ogden AJ, Hicks RJ, Bammert L, Kutay U, Hung S, Sanij E, Hannan RD, Hannan KM, Pearson RB.

Oncotarget. 2016 Aug 2;7(31):48887-48904. doi: 10.18632/oncotarget.10346.

14.

Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.

Devlin JR, Hannan KM, Hein N, Cullinane C, Kusnadi E, Ng PY, George AJ, Shortt J, Bywater MJ, Poortinga G, Sanij E, Kang J, Drygin D, O'Brien S, Johnstone RW, McArthur GA, Hannan RD, Pearson RB.

Cancer Discov. 2016 Jan;6(1):59-70. doi: 10.1158/2159-8290.CD-14-0673. Epub 2015 Oct 21.

15.

Genome wide mapping of UBF binding-sites in mouse and human cell lines.

Diesch J, Hannan RD, Sanij E.

Genom Data. 2015 Jan 5;3:103-5. doi: 10.1016/j.gdata.2014.12.005. eCollection 2015 Mar.

16.

Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.

Brookes S, Gagrica S, Sanij E, Rowe J, Gregory FJ, Hara E, Peters G.

Cell Cycle. 2015;14(8):1164-73. doi: 10.1080/15384101.2015.1010866.

17.

A novel role for the Pol I transcription factor UBTF in maintaining genome stability through the regulation of highly transcribed Pol II genes.

Sanij E, Diesch J, Lesmana A, Poortinga G, Hein N, Lidgerwood G, Cameron DP, Ellul J, Goodall GJ, Wong LH, Dhillon AS, Hamdane N, Rothblum LI, Pearson RB, Haviv I, Moss T, Hannan RD.

Genome Res. 2015 Feb;25(2):201-12. doi: 10.1101/gr.176115.114. Epub 2014 Dec 1.

18.

Conditional inactivation of Upstream Binding Factor reveals its epigenetic functions and the existence of a somatic nucleolar precursor body.

Hamdane N, Stefanovsky VY, Tremblay MG, Németh A, Paquet E, Lessard F, Sanij E, Hannan R, Moss T.

PLoS Genet. 2014 Aug 14;10(8):e1004505. doi: 10.1371/journal.pgen.1004505. eCollection 2014 Aug.

19.

Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells.

Diesch J, Sanij E, Gilan O, Love C, Tran H, Fleming NI, Ellul J, Amalia M, Haviv I, Pearson RB, Tulchinsky E, Mariadason JM, Sieber OM, Hannan RD, Dhillon AS.

PLoS One. 2014 Mar 21;9(3):e88950. doi: 10.1371/journal.pone.0088950. eCollection 2014.

20.

Perturbations at the ribosomal genes loci are at the centre of cellular dysfunction and human disease.

Diesch J, Hannan RD, Sanij E.

Cell Biosci. 2014 Aug 19;4:43. doi: 10.1186/2045-3701-4-43. eCollection 2014. Review.

21.

The nucleolus: an emerging target for cancer therapy.

Hein N, Hannan KM, George AJ, Sanij E, Hannan RD.

Trends Mol Med. 2013 Nov;19(11):643-54. doi: 10.1016/j.molmed.2013.07.005. Epub 2013 Aug 15. Review.

PMID:
23953479
22.

Dysregulation of RNA polymerase I transcription during disease.

Hannan KM, Sanij E, Rothblum LI, Hannan RD, Pearson RB.

Biochim Biophys Acta. 2013 Mar-Apr;1829(3-4):342-60. doi: 10.1016/j.bbagrm.2012.10.014. Epub 2012 Nov 12. Review.

23.

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

Bywater MJ, Poortinga G, Sanij E, Hein N, Peck A, Cullinane C, Wall M, Cluse L, Drygin D, Anderes K, Huser N, Proffitt C, Bliesath J, Haddach M, Schwaebe MK, Ryckman DM, Rice WG, Schmitt C, Lowe SW, Johnstone RW, Pearson RB, McArthur GA, Hannan RD.

Cancer Cell. 2012 Jul 10;22(1):51-65. doi: 10.1016/j.ccr.2012.05.019.

24.

Signaling to the ribosome in cancer--It is more than just mTORC1.

Hannan KM, Sanij E, Hein N, Hannan RD, Pearson RB.

IUBMB Life. 2011 Feb;63(2):79-85. doi: 10.1002/iub.428. Review.

25.

c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation.

Poortinga G, Wall M, Sanij E, Siwicki K, Ellul J, Brown D, Holloway TP, Hannan RD, McArthur GA.

Nucleic Acids Res. 2011 Apr;39(8):3267-81. doi: 10.1093/nar/gkq1205. Epub 2010 Dec 21.

26.

Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.

Drygin D, Lin A, Bliesath J, Ho CB, O'Brien SE, Proffitt C, Omori M, Haddach M, Schwaebe MK, Siddiqui-Jain A, Streiner N, Quin JE, Sanij E, Bywater MJ, Hannan RD, Ryckman D, Anderes K, Rice WG.

Cancer Res. 2011 Feb 15;71(4):1418-30. doi: 10.1158/0008-5472.CAN-10-1728. Epub 2010 Dec 15.

27.

The role of UBF in regulating the structure and dynamics of transcriptionally active rDNA chromatin.

Sanij E, Hannan RD.

Epigenetics. 2009 Aug 16;4(6):374-82. Epub 2009 Aug 6. Review.

PMID:
19717978
28.

UBF levels determine the number of active ribosomal RNA genes in mammals.

Sanij E, Poortinga G, Sharkey K, Hung S, Holloway TP, Quin J, Robb E, Wong LH, Thomas WG, Stefanovsky V, Moss T, Rothblum L, Hannan KM, McArthur GA, Pearson RB, Hannan RD.

J Cell Biol. 2008 Dec 29;183(7):1259-74. doi: 10.1083/jcb.200805146. Epub 2008 Dec 22.

29.

Chromatin organization and expression.

Sanij E, Hannan RD.

Genome Biol. 2008 Apr 14;9(4):305. doi: 10.1186/gb-2008-9-4-305.

30.

Epstein-Barr virus LMP1 blocks p16INK4a-RB pathway by promoting nuclear export of E2F4/5.

Ohtani N, Brennan P, Gaubatz S, Sanij E, Hertzog P, Wolvetang E, Ghysdael J, Rowe M, Hara E.

J Cell Biol. 2003 Jul 21;162(2):173-83. Epub 2003 Jul 14.

31.

Characterization of monoclonal antibodies specific to the transcription factor ETS-2 protein.

Sanij E, Scott B, Wilson T, Xu D, Hertzog P, Wolvetang E.

Immunol Lett. 2003 Mar 3;86(1):63-70.

PMID:
12600747
32.

Characterization and transcriptional analysis of the mouse Chromosome 16 cytokine receptor gene cluster.

Hardy MP, Sanij EP, Hertzog PJ, Owczarek CM.

Mamm Genome. 2003 Feb;14(2):105-18.

PMID:
12584606
33.

Transformation induced by Ewing's sarcoma associated EWS/FLI-1 is suppressed by KRAB/FLI-1.

Chan D, Wilson TJ, Xu D, Cowdery HE, Sanij E, Hertzog PJ, Kola I.

Br J Cancer. 2003 Jan 13;88(1):137-45.

34.

ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway.

Wolvetang EJ, Wilson TJ, Sanij E, Busciglio J, Hatzistavrou T, Seth A, Hertzog PJ, Kola I.

Hum Mol Genet. 2003 Feb 1;12(3):247-55.

PMID:
12554679
35.

Ets-2 is induced by oxidative stress and sensitizes cells to H(2)O(2)-induced apoptosis: implications for Down's syndrome.

Sanij E, Hatzistavrou T, Hertzog P, Kola I, Wolvetang EJ.

Biochem Biophys Res Commun. 2001 Oct 5;287(4):1003-8.

PMID:
11573964

Supplemental Content

Support Center